SCHEMBL8280402

SCHEMBL8280402

CCC(=O)N(C)c1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIB P23284 1/20 0.50
MAPT P10636 3/20 0.49
TP53 P04637 2/20 0.49
POLB P06746 1/20 0.49
ALDH1A1 P00352 4/20 0.49
HTT P42858 2/20 0.49
HSP90AA1 P07900 1/20 0.49
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ESR2 Q92731 1/20 0.47
NOX1 Q9Y5S8 1/20 0.47
MCHR1 Q99705 2/20 0.47
ALOX5 P09917 1/20 0.46
NR1I2 O75469 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765854 0.86 KMT2A (0.43) MAPTPOLBALDH1A1LMNASMN1; SMN2
SCHEMBL11403008 0.85 PPIB (0.50) PPIBMAPTTP53ALDH1A1HTT
SCHEMBL14350964 0.84 HDAC3 (0.53) PPIBMAPTTP53POLBALDH1A1
SCHEMBL6074179 0.84 PPIB (0.49) PPIBMAPTTP53ALDH1A1HTT
SCHEMBL9732732 0.84 ALDH1A1 (0.61) PPIBMAPTTP53ALDH1A1HTT
SCHEMBL7826854 0.84 PPIB (0.49) PPIBMAPTTP53POLBALDH1A1
SCHEMBL30520315 0.84 GSK3B (0.53) PPIBMAPTTP53ALDH1A1HTT
SCHEMBL17336430 0.84 PPIB (0.52) PPIBMAPTTP53ALDH1A1HTT
SCHEMBL8146902 0.83 MTNR1B (0.58) SMN1; SMN2
SCHEMBL30443514 0.83 NR1I2 (0.47) MAPTTP53ALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114456228-B Substituted glycine-3, 5-difluorophenylalanine peptide derivative and preparation method and application thereof 山东大学 2023-09-12 CN disclosed
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
CN-102438977-A Continuous process for the preparation of amides of aliphatic carboxylic acids CLARIANT INT LTD 2012-05-02 CN disclosed
US-7368467-B2 Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders WYETH (US) 2008-05-06 US disclosed
US-20080090891-A1 ION CHANNEL MODULATORS WYETH (US) 2008-04-17 US disclosed
US-20070208064-A1 Ion channel modulators WYETH (US) 2007-09-06 US disclosed
US-20070203194-A1 Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders SCION PHARMACEUTICALS, INC. (US) 2007-08-30 US disclosed
WO-2005087228-A1 ION CHANNEL MODULATORS WYETH (US) 2005-09-22 WO disclosed
WO-2005087750-A1 ION CHANNEL MODULATORS WYETH (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME BRDT, BRD2, BRD4 PPIB 3824/4885MAPT 2520/4885TP53 450/4885
US-20070203194-A1 Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders CACNA1C, CACNA1D, CACNA1G PPIB 2380/4885MAPT 427/4885TP53 3448/4885
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME BRDT, BRD4, BRD1 PPIB 3832/4885MAPT 1845/4885TP53 213/4885
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME BRDT, BRD4, BRD1 PPIB 3264/4885MAPT 2022/4885TP53 677/4885
US-20070208064-A1 Ion channel modulators CACNA1B, CACNA1C, TRPV1 PPIB 2716/4885MAPT 490/4885TP53 4417/4885
US-20080090891-A1 ION CHANNEL MODULATORS CACNA1B, CACNA1C, TRPV1 PPIB 2716/4885MAPT 490/4885TP53 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.